Results 71 to 80 of about 61,480 (319)

Mechanism‐informed machine learning for individualized tacrolimus dose adjustment in the early post‐kidney transplant period

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tacrolimus dosing in the early post‐kidney transplant period is challenging due to a narrow therapeutic index and substantial interindividual pharmacokinetic (PK) variability. This study aimed to develop and validate mechanism‐informed machine learning (ML) models to support individualized tacrolimus dosing during this critical period ...
Hui Yu, Zihan Qin, Logan S. Smith, Jeong M. Park, Hao‐Jie Zhu   +4 more
wiley   +1 more source

CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.

The Journal of toxicological sciences, 2013
Effects of the CYP3A4 intron 6 C>T (CYP3A4*22) polymorphism, which has recently been reported to have a critical role in vivo, were investigated by measuring CYP3A4 protein expression levels and CYP3A4-dependent drug oxidation activities in individual human liver microsomes in vitro.
Maho, Okubo, Norie, Murayama, Makiko, Shimizu, Tsutomu, Shimada, F Peter, Guengerich, Hiroshi, Yamazaki   +5 more
openaire   +2 more sources

Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism

Pharmaceutical Biology, 2020
Context Puerarin and astragaloside IV (AS-IV) are sometimes used together for the treatment of disease in Chinese clinics, however, the drug–drug interaction between puerarin and AS-IV is still unknown.
Huan Zhang, Jiaying Song, Huizhen Dai, Yanchao Liu, Lili Wang   +4 more
doaj   +1 more source

Single-Walled Carbon Nanotubes Inhibit the Cytochrome P450 Enzyme, CYP3A4

Scientific Reports, 2016
We report a detailed computational and experimental study of the interaction of single-walled carbon nanotubes (SWCNTs) with the drug-metabolizing cytochrome P450 enzyme, CYP3A4.
Ramy El-Sayed, K. Bhattacharya, Zonglin Gu, Zaixing Yang, J. Weber, Hu Li, K. Leifer, Yichen Zhao, M. Toprak, R. Zhou, B. Fadeel   +10 more
semanticscholar   +1 more source

Antidiabetic Potential of Ligands from NEIST_PMIB_06, Bacterium Associated with Hawaijar (Fermented Soy Food): Insight from in Vitro and in Silico Studies

ChemFoodChem, EarlyView.
ABSTRACT In this study, a bacterium (NEIST_PMIB_06) was isolated from Hawaijar, a fermented soy food from Manipur, Northeast India. The bacterium was inoculated and incubated to isolate bioactive compounds. Liquid‐liquid extraction was performed to obtain extracts (cell‐free and cell‐based), and their efficacy was evaluated.
A Ibeyaima, Hiranmoy Barman, Prasenjit Manna   +2 more
wiley   +1 more source

A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Rajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, Kyle T. Matschke, Richard Bertz, Robert Croop, Jing Liu   +6 more
wiley   +1 more source

Effects of naringenin on the pharmacokinetics of tofacitinib in rats

Pharmaceutical Biology, 2020
Context Naringenin and tofacitinib are often used together for treatment of rheumatoid arthritis in Chinese clinics. Objective This experiment investigates the effect of naringenin on the pharmacokinetics of tofacitinib in rats.
Bo Wang, Jiquan Shen, Quan Zhou, Deru Meng, Youwu He, Feifei Chen, Shuanghu Wang, Weiping Ji   +7 more
doaj   +1 more source

Flavonoids as CYP3A4 Inhibitors In Vitro

Biomedicines
Flavonoids, a diverse group of polyphenolic compounds found abundantly in fruits, vegetables, and beverages like tea and wine, offer a plethora of health benefits. However, they have a potential interaction with drug metabolism, particularly through the inhibition of the cytochrome P450 3A4 enzyme, the most versatile and abundant enzyme in the liver ...
Martin Kondža, Ivica Brizić, Stela Jokić   +2 more
openaire   +4 more sources

Exposure to CYP3A4‐inducing and CYP3A4‐non‐inducing antiepileptic agents and the risk of fractures [PDF]

Pharmacoepidemiology and Drug Safety, 2011
ABSTRACTPurposeTo evaluate whether exposure to Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)‐inducing antiepileptics increases fracture risk compared to CYP3A4‐non‐inducing antiepileptics.MethodsWe performed a retrospective cohort study of initiators of antiepileptic agents using a UK medical record database (The Health Improvement ...
Hedi, Schelleman, John R, Pollard, Craig, Newcomb, Clyde E, Markowitz, Warren B, Bilker, Mary B, Leonard, Sean, Hennessy   +6 more
openaire   +2 more sources

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens, Dirk Jan A. R. Moes, Yanick Boer, Aiko P. J. de Vries, Dorottya K. de Vries, Danny van der Helm, Soufian Meziyerh, Dave L. Roelen, Stefan Böhringer, Teun Van Gelder, Jesse J. Swen   +10 more
wiley   +1 more source